TCGA-D8-A1XO-01A-11R-A14M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- PROTEIN_SECRETION+0.250
- TGF_BETA_SIGNALING+0.210
- NOTCH_SIGNALING+0.160
- ANDROGEN_RESPONSE+0.130
- KRAS_SIGNALING_UP+0.130
- APICAL_SURFACE+0.120
- BILE_ACID_METABOLISM+0.120
- MITOTIC_SPINDLE+0.120
Top 10 suppressed
- MYC_TARGETS_V2-0.460
- E2F_TARGETS-0.450
- G2M_CHECKPOINT-0.400
- DNA_REPAIR-0.370
- MYC_TARGETS_V1-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- UV_RESPONSE_UP-0.320
- OXIDATIVE_PHOSPHORYLATION-0.310
- CHOLESTEROL_HOMEOSTASIS-0.270
- MTORC1_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.862 |
| 2 | AUR-AFE4-TTP1-A-1-0-R-A741-41 | — | D | 0.837 |
| 3 | TCGA-86-8668-01A-11R-2403-07 | — | cohortA1 | 0.836 |
| 4 | TCGA-D8-A145-01A-11R-A115-07 | — | A | 0.826 |
| 5 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.822 |
| 6 | TCGA-A2-A1G0-01A-11R-A13Q-07 | — | A | 0.821 |
| 7 | TCGA-D8-A27K-01A-11R-A16F-07 | — | A | 0.814 |
| 8 | TCGA-05-4405-01A-21R-1858-07 | — | cohortA1 | 0.814 |
| 9 | TCGA-AR-A24T-01A-11R-A169-07 | — | A | 0.808 |
| 10 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.010 | Idelalisib | — uncovered |